Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

brentuximab

brentuximab is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 0
Pipeline programs 19
News articles 0
Drug details — brentuximab
Class
—
Route
—
Patents
0
Programs
19
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

brentuximab is an FDA-listed pharmaceutical active ingredient.

Key facts

INN brentuximab

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Brentuximab Vedotin Phase 3 · Takeda · Primary Cutaneous Anaplastic Large Cell Lymphoma
  2. Brentuximab Vedotin for Injection Phase 3 · Chinese Academy of · Classical Hodgkin Lymphoma
  3. Brentuximab vedotin Phase 3 · Takeda · Diffuse Large B-cell-lymphoma
  4. Brentuximab vedotin Phase 3 · Pfizer · Diffuse Large B-cell Lymphoma
  5. brentuximab vedotin Phase 3 · Takeda · Hodgkin Lymphoma
  6. ADCETRIS 50 mg powder for concentrate for solution for infusion Phase 2 · Takeda · Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of
  7. Brentuximab Vedotin Phase 2 · Takeda · Enteropathy Associated T-cell Lymphoma
  8. Brentuximab Vedotin Phase 2 · United Therapeutics Europe · Ann Arbor Stage IB Hodgkin Lymphoma

Frequently asked questions

What is brentuximab?

brentuximab is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.